Oxaliplatin-Based Chemotherapy in Patients with Metastatic Colorectal Cancer Aged at Least 75 Years: A Post-Hoc Subgroup Analysis of Three Phase II Trials

Gerardo Rosati(Ospedale San Carlo), Roberto Bordonaro(Ospedale Garibaldi), G Caputo, Giuseppina Blanco, Giorgio Reggiardo(Data Management (Italy)), G. Novello(Azienda Ospedaliero-Universitaria Policlinico - Vittorio Emanuele), Antonio Avallone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Domenico Bilancia(Azienda Ospedaliera Ospedale San Carlo Borromeo), Giuseppe Aprile(Ospedale Santa Maria della Misericordia di Udine), Alfredo Butera(Nuovo Ospedale San Giovanni di Dio), Aniello Tucci, Stefano Cordio(Ospedale San Carlo)
Cancers
April 24, 2019
10.3390/cancers11040578
Cited by 6

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
|NEJM Evidence|2022|1.1k
Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III Trial
|Journal of Clinical Oncology|2011|763
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
|The Lancet|2023|701
Gemcitabine Plus Vinorelbine Versus Vinorelbine Alone in Elderly Patients With Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2000|452